Advertising data platform LiveRamp (NYSE:RAMP) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 9.8% year on year to $188.7 million. Guidance for next quarter’s revenue was better than expected at $191 million at the midpoint, 0.9% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 7.1% above analysts’ consensus estimates.
Battery manufacturer EnerSys (NYSE:ENS) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7% year on year to $974.8 million. On the other hand, next quarter’s revenue guidance of $850 million was less impressive, coming in 7% below analysts’ estimates. Its non-GAAP profit of $2.97 per share was 6.8% above analysts’ consensus estimates.
Data visualization and business intelligence company Domo (NASDAQ:DOMO) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $80.11 million. Guidance for next quarter’s revenue was better than expected at $78 million at the midpoint, 0.7% above analysts’ estimates. Its non-GAAP loss of $0.09 per share was 53.6% above analysts’ consensus estimates.
Data warehouse-as-a-service Snowflake (NYSE:SNOW) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 25.7% year on year to $1.04 billion. Its non-GAAP profit of $0.24 per share was 13.1% above analysts’ consensus estimates.
Video conferencing platform Zoom (NASDAQ:ZM) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.9% year on year to $1.17 billion. Guidance for next quarter’s revenue was better than expected at $1.20 billion at the midpoint, 0.6% above analysts’ estimates. Its non-GAAP profit of $1.43 per share was 9.5% above analysts’ consensus estimates.
Clothing and accessories retailer Urban Outfitters (NASDAQ:URBN) announced better-than-expected revenue in Q1 CY2025, with sales up 10.7% year on year to $1.33 billion. Its GAAP profit of $1.16 per share was 39.6% above analysts’ consensus estimates.
Shares of health insurance company UnitedHealth (NYSE:UNH) fell 5.5% in the afternoon session after HSBC analysts downgraded the stock's rating from Neutral to Sell, adding that the recent sell-off had yet to provide a cheap opportunity to buy. The analysts also cited key reasons for the concerns, including "higher medical costs, political pressure on drug prices, and lower overall profitability ahead, especially if there are cuts to Medicaid spending.".
A number of stocks fell in the afternoon session after the major indices fell further in the afternoon (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit. A poor auction for 20-year U.S. Treasury bonds further raised concerns, as weak demand implies investors are becoming more cautious about holding long-dated U.S. debt.
Power resiliency solutions provider American Superconductor (NASDAQ:AMSC) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 58.6% year on year to $66.66 million. On top of that, next quarter’s revenue guidance ($66 million at the midpoint) was surprisingly good and 8.8% above what analysts were expecting. Its non-GAAP profit of $0.12 per share was 24.1% above analysts’ consensus estimates.
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit. A poor auction for 20-year U.S. Treasury bonds further raised concerns, as weak demand implies investors are becoming more cautious about holding long-dated U.S. debt.
A number of stocks fell in the afternoon session after the major indices fell further in the afternoon (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit.
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit. A poor auction for 20-year U.S. Treasury bonds further raised concerns, as weak demand implies investors are becoming more cautious about holding long-dated U.S. debt.
Zoom stock climbed after the communications software maker reported Q1 earnings that topped estimates while revenue guidance edged by Wall Street targets.
UroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution.
